Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
June 14, 2019 07:00 ET
|
Kura Oncology, Inc.
– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an...
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
May 07, 2019 16:05 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA...
Kura Oncology to Report First Quarter 2019 Financial Results
April 30, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
April 02, 2019 16:04 ET
|
Kura Oncology, Inc.
– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – –...
Kura Oncology to Participate in Two Upcoming Investor Conferences
March 06, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
March 05, 2019 07:30 ET
|
Kura Oncology, Inc.
– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in...
Kura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at SVB Leerink Global Healthcare Conference
February 20, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
University of Colorado Hospital Announces new Center for Lungs and Breathing
October 01, 2015 09:05 ET
|
UCHealth
AURORA, COLO., Oct. 1, 2015 (GLOBE NEWSWIRE) -- UCHealth's University of Colorado Hospital (UCH), a national leader in pulmonology, cancer and upper airway disorders, opens its new multidisciplinary...